Metoprolol Stada (Metoprolol Tartrate)

Metoprolol Stada is a beta‑adrenergic blocker used in several cardiovascular conditions.

• Hypertension: lowers systolic and diastolic pressure by reducing heart rate and contractility.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain during exertion.
• Post‑myocardial infarction: reduces risk of recurrent infarction and improves survival.
• Chronic heart failure: improves ventricular function and reduces hospitalisation.
• Cardiac arrhythmias: controls heart rate in supraventricular tachycardia and atrial fibrillation.

• Metoprolol Tartrate selectively antagonises β1‑adrenergic receptors in cardiac tissue, inhibiting sympathetic stimulation. This blockade reduces cyclic AMP formation, leading to decreased calcium influx, slower pacemaker activity, reduced myocardial contractility, and lower cardiac output, which together lower blood pressure and myocardial oxygen consumption.

Metoprolol Stada may cause a range of adverse reactions.

Common Side Effects

• Fatigue or tiredness
• Dizziness, especially on standing
• Cold extremities or reduced peripheral circulation
• Gastrointestinal upset such as nausea or abdominal discomfort
• Sleep disturbances, including vivid dreams

Serious or Rare Side Effects

• Bradycardia or symptomatic heart block
• Severe hypotension with syncope
• Exacerbation of heart failure symptoms
• Bronchospasm in patients with reactive airway disease
• Allergic reactions such as rash, pruritus, or angioedema

Before initiating Metoprolol Stada, consider the following precautions.

• Cardiovascular assessment: evaluate baseline heart rate, blood pressure, and cardiac function.
• Respiratory status: avoid in uncontrolled asthma or severe chronic obstructive pulmonary disease.
• Diabetes monitoring: may mask hypoglycaemia symptoms; adjust glucose monitoring accordingly.
• Concomitant drugs: review for potential additive bradycardic or hypotensive agents.
• Renal or hepatic impairment: dose adjustment may be required based on clinical judgment.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Metoprolol Stada can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Non‑selective beta‑blockers or other cardio‑selective agents: risk of excessive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): may cause profound heart‑rate slowing and AV‑block.

Moderate Interactions (Monitor Closely)

• Antidiabetic drugs (insulin, sulfonylureas): may mask hypoglycaemia signs.
• Antidepressants (SSRIs, SNRIs): can increase plasma metoprolol levels.
• NSAIDs or COX‑2 inhibitors: may reduce antihypertensive effect.
• Clonidine withdrawal: abrupt cessation can lead to rebound hypertension when combined with metoprolol.